Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05801679 · ClinicalTrials.gov registry record · Phase 3
Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo
A Phase 3 study of Surgery, sponsored by Endeavor Health.
- Active
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
- 1
- Study location
NCT05801679 is a Phase 3 study of Surgery that is active but no longer recruiting, run by Endeavor Health. The registered enrollment target is 175 participants, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05801679, a Phase 3 study of Surgery, is active but no longer recruiting, sponsored by Endeavor Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective randomized blinded controlled trial that will enroll 175 subjects undergoing cardiopulmonary bypass at NorthShore University HealthSystem. The purpose of this study is to compare clinical outcomes in elective and urgent cardiac surgical patients at NorthShore University HealthSystem when receiving sugammadex, a common neuromuscular blockade reversal drug given after surgery and before the breathing tube is removed vs. those patients who do not receive sugammadex (placebo) group. The Investigators will compare the following outcomes in both the sugammadex and placebo groups during patients hospital stay: # of patients who have the breathing tube removed within 6 hour of the end of surgery, time it takes to remove the breathing tube after surgery, ICU and hospital length of stay, cost of the ICU stay, time to achieve a train of four ratio of \> or equal to 0.9, whether patients develop pneumonia or not, whether they require the breathing tube to be replaced during their hospital stay and to compare the nursing perception of patients recovery within first 24 hours of their ICU stay.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sugammadex
Study Locations (1)
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2025-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05801679
The ClinicalTrials.gov registry entry for NCT05801679 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05801679 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05801679 about?
NCT05801679 is a clinical study titled "Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo". This is a prospective randomized blinded controlled trial that will enroll 175 subjects undergoing cardiopulmonary bypass at NorthShore University HealthSystem. The purpose of this study is to compare clinical outcomes in elective and urgent cardiac surgical patients at NorthShore University HealthS...
What is the current status of trial NCT05801679?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2023-07-03. Estimated completion is 2025-10.
What conditions does trial NCT05801679 study?
This clinical trial studies the following conditions: Surgery.
What interventions are being tested in trial NCT05801679?
The interventions under investigation include: Placebo (OTHER), Sugammadex (DRUG).
Who is sponsoring clinical trial NCT05801679?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05801679 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
Sentinel Node Biopsy in Endometrial Cancer
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant
COMPLETED · Phase 3
-
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.